MVA-SARS-2-ST

BIOLOGICAL2 trials

Sponsors

Universitätsklinikum Hamburg-Eppendorf, Hannover Medical School

Conditions

COVID-19 VaccinesCovid19

Phase 1

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19

CompletedNCT04895449

Universitätsklinikum Hamburg-EppendorfCovid19

Start: 2021-07-16End: 2022-11-08Updated: 2023-01-18

Safety, Reactogenicity and Immunogenicity of a Novel MVA-SARS-2-ST Vaccine Candidate

TerminatedNCT05226390

Hannover Medical SchoolCOVID-19 Vaccines

Start: 2022-02-24End: 2023-11-17Updated: 2026-08-21

Related Papers

MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity

Frontiers in Immunology2024-12-192 citations

2343. SARS-CoV-2 Spike Conformation Essentially Influences Vaccine Immunogenicity – Results from Two Clinical Phase I Trials of the Vector Vaccine Candidates MVA-SARS-2-S and MVA-SARS-2-ST

Open Forum Infectious Diseases2023-11-27

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

Nature Communications2022-07-1920 citations

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial.

2022-03-0941 citations